Radiopharmaceutical Manufacturing: A High-Stakes Race Against Time

From the executive boardrooms of pharma companies to academic research centers, one fact is becoming unmistakably clear: making radiopharmaceuticals is an inherently complex, high-stakes endeavor, and the industry is racing to manage the risks of these perishable therapies before the clock runs out The post Radiopharmaceutical Manufacturing: A High-Stakes Race Against Time appeared first on…

Read More

The Role of Medication Delivery in Non-Adherence

For GLP-1 receptor agonists specifically, adherence challenges are a major concern, as these medications require long-term use to achieve meaningful health benefits in chronic conditions like diabetes and obesity. The post The Role of Medication Delivery in Non-Adherence appeared first on MedCity News.

Read More

Goodbye, American Science

By KIM BELLARD Many people don’t realize it, but a hundred years ago America was something of a scientific backwater. Oh, sure, we had the occasional Nobel laureate, but the center of science was in Europe, particularly Germany. Then in the early 1930’s the Nazis decided that “purity” – of political ideas, of blood –…

Read More

How hard is it to prove you have coverage?

A friend of mine who wants to stay anonymous (for now at any rate) had a crazy waste of time proving that he was eligibile for a medication on his plan. I thought his story might trigger a few of you! And yes Optum is of course part of United HealthGroup–Matthew Holt Here is the…

Read More

More evidence that there are diminishing marginal returns to quality of life gains

Quality-adjusted life years (QALYs) are commonly used to evaluate the impact of new medical technologies on patient mortality and morbidity. However, use of QALYs Many authors have discussed the fact that standard assumptions result in utility functions that are unrealistically linear and separable, overlooking the diminishing marginal utility a fundamental property of utility functions in…

Read More